Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus
- 1 December 1996
- journal article
- Published by SAGE Publications in Lupus
- Vol. 5 (6) , 598-601
- https://doi.org/10.1177/096120339600500607
Abstract
Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q506. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous thrombosis and 8 (10%) had a cerebral infarction caused by occlusion of cerebral vessels. Twenty-six (33%) SLE patients were aCL positive and 8 (10%) were heterozygous for the factor V mutation. Only one of the patients with venous thrombosis and one of the patients with cerebral thrombosis had the FV:Q506 mutation, whereas 3 patients with venous thrombosis and 5 patients with cerebral infarction were aCL positive. Eleven of 19 patients with heart valve disease were aCL positive, a statistically significant association ( P = 0.01). In conclusion, we found no statistically significant association between venous thrombosis and FV:Q506 mutation or venous thrombosis and aCL positivity. There was, however, an association between heart valve disease and aCL positivity.Keywords
This publication has 45 references indexed in Scilit:
- The protein C anticoagulant system: Inherited defects as basis for venous thrombosisThrombosis Research, 1995
- Resistance to activated protein C caused by a Factor V gene mutationCurrent Opinion in Hematology, 1995
- Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophiliaBlood, 1994
- Activated protein C resistance caused by Arg506Gln mutation in factor VaThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Resistance to Activated Protein C as a Basis for Venous ThrombosisNew England Journal of Medicine, 1994
- The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjectsBlood Coagulation & Fibrinolysis, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]Blood, 1993
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proceedings of the National Academy of Sciences, 1993